trending Market Intelligence /marketintelligence/en/news-insights/trending/XNffDYERt_AVOBKNbhqbeg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Gilead's HIV-1 medicine Biktarvy wins approval in China

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Gilead's HIV-1 medicine Biktarvy wins approval in China

Gilead Sciences Inc. said its once-daily HIV-1 drug Biktarvy has been approved by the China National Medical Products Administration.

The Foster City, Calif.-based biotechnology company's Biktarvy tablet combines bictegravir and two other drugs, emtricitabine and tenofovir alafenamide — the components of Gilead's HIV drug Descovy.

Biktarvy's approval in China is based on data from four late-stage studies in 2,414 patients. Two of these phase 3 trials, dubbed 1489 and 1490, were carried out in HIV-1 infected adults who had never received any treatment.

The other two trials, known as 1844 and 1878, enrolled patients whose viral load was at an undetectable level and they had switched from another antiretroviral regimen. Undetected viral load does not mean a person is cured as HIV still remains in the body and will return to detectable levels once the treatment is discontinued.

After 48 weeks of treatment, Biktarvy showed that it worked as well as a comparator antiretroviral treatment. None of the participants in any of the four studies developed treatment-emergent virologic resistance while taking Biktarvy, and no patients discontinued Biktarvy due to renal, bone or hepatic adverse events.

The single-tablet regimen was approved to treat HIV-1 infection in the U.S. and Japan in February 2018 and March 2019, respectively. Total sales of Biktarvy for the second quarter of 2019 were $1.12 billion.